| Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial R Ella, KM Vadrevu, H Jogdand, S Prasad, S Reddy, V Sarangi, ... The Lancet Infectious Diseases 21 (5), 637-646, 2021 | 450 | 2021 |
| Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a … R Ella, S Reddy, H Jogdand, V Sarangi, B Ganneru, S Prasad, D Das, ... The Lancet Infectious Diseases 21 (7), 950-961, 2021 | 361 | 2021 |
| Epidemiological profile of snake-bite cases from Andhra Pradesh using immunoanalytical approach G Brunda, RB Sashidhar Indian journal of medical research 125 (5), 661-668, 2007 | 156 | 2007 |
| The p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit R Jalah, M Rosati, B Ganneru, GR Pilkington, A Valentin, V Kulkarni, ... Journal of Biological Chemistry 288 (9), 6763-6776, 2013 | 94 | 2013 |
| IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques R Jalah, V Patel, V Kulkarni, M Rosati, C Alicea, B Ganneru, ... Human vaccines & immunotherapeutics 8 (11), 1620-1629, 2012 | 80 | 2012 |
| Use of egg yolk antibody (IgY) as an immunoanalytical tool in the detection of Indian cobra (Naja naja naja) venom in biological samples of forensic origin G Brunda, RB Sashidhar, RK Sarin Toxicon 48 (2), 183-194, 2006 | 69 | 2006 |
| Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation B Ganneru, H Jogdand, VK Daram, D Das, NR Molugu, SD Prasad, ... Iscience 24 (4), 2021 | 59 | 2021 |
| HIV-1 p24gag Derived Conserved Element DNA Vaccine Increases the Breadth of Immune Response in Mice V Kulkarni, M Rosati, A Valentin, B Ganneru, AK Singh, J Yan, M Rolland, ... PloS one 8 (3), e60245, 2013 | 59 | 2013 |
| Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune … R Ella, S Reddy, H Jogdand, V Sarangi, B Ganneru, S Prasad, D Das, ... medRxiv, 2020.12. 21.20248643, 2020 | 48 | 2020 |
| Evaluation of safety and immunogenicity of an adjuvanted, TH-1 skewed, whole virion InactivatedSARS-CoV-2 vaccine-BBV152 B Ganneru, H Jogdand, VK Dharam, NR Molugu, SD Prasad, S Vellimudu, ... BioRxiv, 2020.09. 09.285445, 2020 | 38 | 2020 |
| Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques V Kulkarni, R Jalah, B Ganneru, C Bergamaschi, C Alicea, ... Vaccine 29 (39), 6742-6754, 2011 | 30 | 2011 |
| A phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152 R Ella, KM Vadrevu, H Jogdand, S Prasad, S Reddy, V Sarangi, ... MedRxiv, 2020.12. 11.20210419, 2020 | 27 | 2020 |
| Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants KM Vadrevu, B Ganneru, S Reddy, H Jogdand, D Raju, G Sapkal, ... Scientific reports 12 (1), 12038, 2022 | 26 | 2022 |
| Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation … KM Vadrevu, S Reddy, H Jogdand, B Ganneru, N Mirza, VN Tripathy, ... The Lancet Infectious Diseases 22 (9), 1303-1312, 2022 | 23 | 2022 |
| Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®) C Singh, S Verma, P Reddy, MS Diamond, DT Curiel, C Patel, MK Jain, ... npj Vaccines 8 (1), 125, 2023 | 15 | 2023 |
| DNA vaccination by intradermal electroporation induces long‐lasting immune responses in rhesus macaques V Kulkarni, M Rosati, R Jalah, B Ganneru, C Alicea, L Yu, Y Guan, ... Journal of medical primatology 43 (5), 329-340, 2014 | 12 | 2014 |
| Quantitation of Indian Krait (Bungarus caeruleus) Venom in Human Specimens of Forensic Origin by Indirect Competitive Inhibition Enzyme-Linked Immunosorbent … G Brunda, BS Rao, RK Sarin Journal of AOAC International 89 (5), 1360-1366, 2006 | 10 | 2006 |
| Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (BBV152) in children from 2 to 18 years of age: an open-label, age-de-escalation phase 2/3 study KM Vadrevu, S Reddy, H Jogdand, B Ganneru, N Mirza, VN Tripathy, ... medRxiv, 2021.12. 28.21268468, 2021 | 9 | 2021 |
| Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial KM Vadrevu, B Ganneru, S Reddy, H Jogdand, D Raju, U Praturi, ... MedRxiv, 2022.01. 05.22268777, 2022 | 7 | 2022 |
| Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152: A phase 1, double-blind, randomised control trial R Ella, KM Vadrevu, H Jogdand, SD Prasad, S Reddy, V Sarangi, ... | 5 | 2020 |
